Abstract: The present invention provides soluble CTLA4 mutant molecules which bind CD80 and/or CD86 antigen.

Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Abstract: There is disclosed a structural genus of compounds, defined according to coordinates in three-dimensional space, that bind amino moieties on neighboring residues in a tyrosine residue 29 pocket of the matrix protein component of the HIV-1 preintegration complex (PIC), thereby preventing the PIC from binding to karyopherin ? and preventing nuclear importation and integration of the HIV-1 viral genome into the host cell DNA, thereby preventing viral infection. The compounds may be utilized alone or in combinations with known inhibitors for preventing or inhibiting HIV-1 infection.

Abstract: A system and method for identifying a small group of compounds representative of a larger set of compounds is disclosed. The system obtains one or more descriptors, determines the median value for the values of each descriptor for a set of compounds, partitions the set of compounds into a plurality of partitions using each median value for the set of compounds, and selects compounds from each of the partitions to form a subgroup representative of the set of compounds. A system and method for virtual compound screening is also disclosed. The system recursively partitions a set of compounds based on descriptor median values where the partitions which have at least two bait compounds are recombined and repartitioned until a desired number of compounds remain in the partition.

Abstract: The invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD86 antigen than wildtype CTLA4.

Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wildtype CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 and M97-G107 are mutated. The mutant molecules of the invention also include a second amino acid sequence which increases the solubility of the mutant molecule.

Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein.

Abstract: Purified ICOS polypeptides are described, as well as nucleic acids encoding the polypeptides, vectors including the nucleic acids, host cells containing the vectors, and methods for using the polypeptides, nucleic acids, and host cells.

Abstract: The present invention provides methods for treating or preventing cancer or neoplastic disease comprising administering to a patient a compound having the features of a pharmacophore for human anti-apotptotic Bcl protein inhibitors or identified by the in vitro methods for identifying anti-apotptotic-Bcl protein inhibitors. Also disclosed are methods for inhibiting the growth of a cancer cell or a neoplastic cell, comprising contacting the cancer cell or neoplastic cell with a compound having the features of a pharmacophore for human anti-apoptotic-Bcl protein inhibitors.

Abstract: The invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD86 antigen than wildtype CTLA4.

Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Abstract: The present invention provides novel soluble CTLA4Ig molecules having modified Ig domains.

Abstract: A method for the treatment of T cell mediated disorders is described. The method involves administering to a subject a therapeutically effective amount of an anti-human CD40 antibody. Disease states suitable for treatment with this method include graft versus host disease and transplant rejection and auto immune disease such as type I diabetes, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and myesthenia gravis.

Abstract: The invention provides antibodies and other binding agents that bind specifically to SRCR domains of human CD6 (hCD6) and have advantageous properties, including the capacity to substantially inhibit binding of activated leukocyte adhesion molecule (ALCAM) to hCD6. The binding agents of the invention are useful, inter alia, in methods for screening peptides and drugs that also bind to hCD6 and/or modulate ALCAM binding to hCD6, as well as in diagnostic and therapeutic methods for management and treatment of inflammatory and autoimmune diseases.

Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein.

Abstract: The Applicants have discovered humanized anti-human CD40 antibodies which block the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent antigens, collagen induced arthritis, and skin transplantation, and are also useful for their anti-inflammatory properties.

Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen. In another embodiment the expression vector encodes a bispecific fusion protein, which vector comprises a recombinant bispecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen and a DNA sequence encoding a second binding domain capable of binding a cell surface antigen, each domain capable of binding a different antigen. The present invention also provides a method for producing a biologically active monospecific or bispecific fusion protein in a mammalian cell.

Abstract: The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises administering an alpha-2-antiplasmin-binding molecule capable of preventing inhibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministrating an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent.

Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins including CTLA4/CD28 chimeric proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.